Erythropoietin Drugs Market By Drug Class (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa), By Drug Type (Biologics, Biosimilar), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Application (Cancer, Renal Disease, Hematology, Neurology), Industry Trends, Estimation & Forecast, 2018 - 2025

Erythropoietin Drugs Market is expected to grow with a CAGR of 7% during the forecast period of 2018 to 2025

Market Overview:

Erythropoietin (EPO), also known as hematopoietin, is a glycoprotein hormone produced by kidneys, responsible for stimulating the bone marrow to produce red blood cells within the body. Erythropoietin drugs market is witnessing an impressive growth with the increasing prevalence of anemia among women, especially in the developing and under developed countries such as India, Nigeria and many others. Moreover, rising number of patients suffering from chronic diseases such as cancer and chronic kidney disease is another factor which is driving the market growth. According to American Cancer Society, in 2018, 1,735,350 new cancer cases are anticipated to be diagnosed. In addition to this, patent expiration of the branded drugs lets the generic and biosimilar manufacturers to enter the market. These drugs are cheap, and hence are affordable for every economic group of the society. Additionally, reimbursement policies for patients is yet another factor responsible for the growth of erythropoietin drugs market. However, side effects of erythropoietin drugs is creating hesitation among the patients to adopt these drugs, thus, hampering the growth of the erythropoietin drugs market. On the other hand, favorable government initiatives in order to promote the usage of generic drugs can put forward a lucrative growth platform for the drug manufacturers involved in generic drugs. For example, the U.S. Food and Drug Administration has recently approved Retacrit (epoetin alfa-epbx) as a drug biosimilar to Epogen/Procrit (epoetin alfa) from Amgen Inc, to treat anemia caused by chronic kidney disease, chemotherapy. It is also approved to be used before and after the surgeries causing excessive blood loss, as it reduces the chances of red blood cell transfusion. The report provides detailed qualitative and quantitative analysis of the Erythropoietin Drugs market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely drug class, drug type, distribution channel, application in each of the major regions.

Erythropoietin Drugs Market Segmentation

By Drug Class • Epoetin-alfa • Epoetin-beta • Darbepoetin-alfa By Drug Type • Biologics • Biosimilar By Distribution Channel  • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy By Application • Cancer • Renal Disease • Hematology • Neurology • Others By geography • North America o U.S. o Canada o Mexico • Europe o U.K. o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o China o Japan o India o Korea o Rest of APAC • South America o Brazil o Rest of South America • Rest of the World o Middle East o Africa

CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC DESK RESEARCH
1.1.2. ERC DATA SYNTHESIS
1.1.3. DATA VALIDATION AND MARKET FEEDBACK
1.1.4. ERC DATA SOURCES

CHAPTER 2. ERYTHROPOIETIN DRUGS MARKET OVERVIEW
2.1. ERYTHROPOIETIN DRUGS MARKET INTRODUCTION
2.2. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
2.2.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION (VOLUME) AND GROWTH RATE (%), (2017-2025)
2.3. GLOBAL ERYTHROPOIETIN DRUGS MARKET CAPACITY AND GROWTH RATE, 2017-2025
2.3.1. GLOBAL ERYTHROPOIETIN DRUGS CAPACITY (VOLUME) AND GROWTH RATE (%), (2017-2025)
2.4. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
2.4.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND GROWTH RATE (%), (2017-2025)
2.5. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
2.5.1. GLOBAL ERYTHROPOIETIN DRUGS CONSUMPTION (VOLUME) AND GROWTH RATE (%), (2017-2025)

CHAPTER 3. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DRUG CLASS, 2017-2025
3.1. EPOETIN-ALFA
3.2. EPOETIN-BETA
3.3. DARBEPOETIN-ALFA
3.4. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY DRUG CLASS, 2017-2025
3.4.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY DRUG CLASS, 2017-2025
3.4.2. EPOETIN-ALFA MARKET REVENUE AND GROWTH RATE, 2017-2025
3.4.3. EPOETIN-BETA MARKET REVENUE AND GROWTH RATE, 2017-2025
3.4.4. DARBEPOETIN-ALFA MARKET REVENUE AND GROWTH RATE, 2017-2025
3.5. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION BY DRUG CLASS, 2017-2025
3.5.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY DRUG CLASS, 2017-2025
3.5.2. EPOETIN-ALFA MARKET PRODUCTION AND GROWTH RATE, 2017-2025
3.5.3. EPOETIN-BETA MARKET PRODUCTION AND GROWTH RATE, 2017-2025
3.5.4. DARBEPOETIN-ALFA MARKET PRODUCTION AND GROWTH RATE, 2017-2025

CHAPTER 4. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY APPLICATION, 2017-2025
4.1. CANCER
4.2. RENAL DISEASE
4.3. HEMATOLOGY
4.4. NEUROLOGY
4.5. OTHERS
4.6. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY APPLICATION, 2017-2025
4.6.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY APPLICATION, 2017-2025
4.6.2. CANCER MARKET REVENUE AND GROWTH RATE, 2017-2025
4.6.3. RENAL DISEASE MARKET REVENUE AND GROWTH RATE, 2017-2025
4.6.4. HEMATOLOGY MARKET REVENUE AND GROWTH RATE, 2017-2025
4.7. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION BY APPLICATION, 2017-2025
4.7.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY APPLICATION, 2017-2025
4.7.2. CANCER MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
4.7.3. RENAL DISEASE MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
4.7.4. HEMATOLOGY MARKET CONSUMPTION AND GROWTH RATE, 2017-2025

CHAPTER 5. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DRUG TYPE, 2017-2025
5.1. BIOLOGICS
5.2. BIOSIMILAR

CHAPTER 6. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY DISTRIBUTION CHANNEL, 2017-2025
6.1. HOSPITAL PHARMACY
6.2. RETAIL PHARMACY
6.3. ONLINE PHARMACY

CHAPTER 7. GLOBAL ERYTHROPOIETIN DRUGS MARKET BY REGION, 2017-2025
7.1. NORTH AMERICA
7.1.1. U.S.
7.1.2. CANADA
7.1.3. MEXICO
7.2. EUROPE
7.2.1. U.K.
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. ITALY
7.2.5. SPAIN
7.2.6. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. CHINA
7.3.2. JAPAN
7.3.3. INDIA
7.3.4. KOREA
7.3.5. REST OF APAC
7.4. SOUTH AMERICA
7.4.1. BRAZIL
7.4.2. REST OF SOUTH AMERICA
7.5. REST OF THE WORLD
7.5.1. MIDDLE EAST
7.5.2. AFRICA
7.6. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE BY REGION, 2017-2025
7.6.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY REGION, 2017-2025
7.6.2. NORTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
7.6.3. EUROPE MARKET REVENUE AND GROWTH RATE, 2017-2025
7.6.4. ASIA PACIFIC MARKET REVENUE AND GROWTH RATE, 2017-2025
7.6.5. SOUTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
7.6.6. REST OF THE WORLD MARKET REVENUE AND GROWTH RATE, 2017-2025

CHAPTER 8. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
8.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
8.1.1. GLOBAL ERYTHROPOIETIN DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
8.1.2. GLOBAL ERYTHROPOIETIN DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
8.1.3. NORTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
8.1.4. EUROPE MARKET PRODUCTION AND CONSUMPTION, 2017-2025
8.1.5. ASIA PACIFIC MARKET PRODUCTION AND CONSUMPTION, 2017-2025
8.1.6. SOUTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
8.1.7. REST OF THE WORLD MARKET PRODUCTION AND CONSUMPTION, 2017-2025

CHAPTER 9. MARKET DETERMINANTS
9.1. MARKET DRIVERS
9.2. MARKET RESTRAINTS
9.3. MARKET OPPORTUNITIES
9.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 10. GLOBAL ERYTHROPOIETIN DRUGS MARKET COMPETITION BY MANUFACTURERS
10.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
10.1.1. GLOBAL ERYTHROPOIETIN DRUGS PRODUCTION (VOLUME) AND SHARE (%) BY MANUFACTURERS (2017-2025)
10.2. GLOBAL ERYTHROPOIETIN DRUGS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
10.2.1. GLOBAL ERYTHROPOIETIN DRUGS REVENUE (MILLION USD) AND SHARE (%) BY MANUFACTURERS (2017-2025)
10.3. ERYTHROPOIETIN DRUGS MARKET COMPETITIVE SITUATION AND TRENDS
10.3.1. ERYTHROPOIETIN DRUGS MARKET SHARE (%) OF TOP 3 MANUFACTURERS
10.3.2. ERYTHROPOIETIN DRUGS MARKET SHARE (%) OF TOP 5 MANUFACTURERS

CHAPTER 11. GLOBAL ERYTHROPOIETIN DRUGS MANUFACTURERS ANALYSIS
11.1. LG LIFE SCIENCES LIMITED
11.1.1. BUSINESS OVERVIEW
11.1.2. COMPANY BASIC INFORMATION
11.1.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.1.4. LG LIFE SCIENCES LIMITED ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.2. RANBAXY LABORATORIES LTD
11.2.1. BUSINESS OVERVIEW
11.2.2. COMPANY BASIC INFORMATION
11.2.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.2.4. RANBAXY LABORATORIES LTD ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD
11.3.1. BUSINESS OVERVIEW
11.3.2. COMPANY BASIC INFORMATION
11.3.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.3.4. TEVA PHARMACEUTICAL INDUSTRIES LTD ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.4. BIOCON LIMITED
11.4.1. BUSINESS OVERVIEW
11.4.2. COMPANY BASIC INFORMATION
11.4.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.4.4. BIOCON LIMITED ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.5. HOFFMANN-LA ROCHE AG
11.5.1. BUSINESS OVERVIEW
11.5.2. COMPANY BASIC INFORMATION
11.5.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.5.4. HOFFMANN-LA ROCHE AG ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.6. HOSPIRA INC.
11.6.1. BUSINESS OVERVIEW
11.6.2. COMPANY BASIC INFORMATION
11.6.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.6.4. HOSPIRA INC. ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.7. PFIZER INC.
11.7.1. BUSINESS OVERVIEW
11.7.2. COMPANY BASIC INFORMATION
11.7.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.7.4. PFIZER INC. ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.8. JOHNSON & JOHNSON LLC
11.8.1. BUSINESS OVERVIEW
11.8.2. COMPANY BASIC INFORMATION
11.8.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.8.4. JOHNSON & JOHNSON LLC ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.9. NOVARTIS INTERNATIONAL AG
11.9.1. BUSINESS OVERVIEW
11.9.2. COMPANY BASIC INFORMATION
11.9.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.9.4. NOVARTIS INTERNATIONAL AG ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
11.10. GLAXOSMITHKLINE PLC
11.10.1. BUSINESS OVERVIEW
11.10.2. COMPANY BASIC INFORMATION
11.10.3. ERYTHROPOIETIN DRUGS PRODUCT DETAILS
11.10.4. GLAXOSMITHKLINE PLC ERYTHROPOIETIN DRUGS PRODUCTION, REVENUE AND GROSS MARGIN

CHAPTER 12. ERYTHROPOIETIN DRUGS MARKET VALUE CHAIN ANALYSIS
12.1. ERYTHROPOIETIN DRUGS INDUSTRIAL CHAIN ANALYSIS
12.2. ERYTHROPOIETIN DRUGS KEY RAW MATERIALS ANALYSIS
12.2.1. KEY RAW MATERIALS
12.2.2. PRICE TREND OF KEY RAW MATERIALS
12.2.3. KEY SUPPLIERS OF RAW MATERIALS
12.3. CONSUMER ANALYSIS
12.3.1. CONSUMER 1
12.3.2. CONSUMER 2
12.3.3. CONSUMER 3
12.3.4. CONSUMER 4

• LG Life Sciences Limited
• Ranbaxy Laboratories Ltd
• Teva Pharmaceutical Industries Ltd
• Biocon Limited
• Hoffmann-La Roche AG
• Hospira Inc.
• Pfizer Inc.
• Johnson & Johnson LLC
• Novartis International AG.
• Amgen Inc
• GlaxoSmithKline plc
• Merck & Co
• Wockhardt Ltd.

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS